Pentasa Sachets licensed for paediatric use

on the 28 June 2010

Pentasa Sachets (mesalazine) are now licensed for use in children with mild to moderate ulcerative colitis, from the age of 6 years.

As a general rule, half the adult dose may be given to children up to a body weight of 40kg, and the normal adult dose to those weighing more than 40kg.

Pentasa Sachets were previously contraindicated under the age of 12 years. The only other mesalazine preparation currently available for use in children is Salofalk Granules.

View Pentasa drug record

Further information: Ferring Pharmaceuticals

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

The most up-to-date drug information at your fingertips.

  • Get the prescribing support you need.
  • Register today for full access to the MIMS database, plus tables and guideline summaries, new and deleted products and consultation tools.
Register Now
Already Registered?

Forgotten password?

MIMS Clinics

Prescribing news and resources for key therapeutic areas, collated by the MIMS editors.

Twitter  

More from MIMS

New once-weekly GLP-1 agonist for diabetes

New once-weekly GLP-1 agonist for diabetes

Ozempic (semaglutide) is a glucagon-like peptide-1...

Gluten-free prescribing restricted to bread and mixes

Gluten-free prescribing restricted to bread and mixes

GPs in England are no longer able to prescribe gluten-free...

New vitamin D deficiency thresholds recommended

New vitamin D deficiency thresholds recommended

The National Osteoporosis Society (NOS) has updated...

SGLT2 inhibitors associated with increased risk of lower-limb amputation in new study

SGLT2 inhibitors associated with increased risk of lower-limb amputation in new study

SGLT2 inhibitors may be linked to a doubling in the...